- Home
- ZENV vs ARMP Comparison
ZENV vs ARMP Comparison
Compare ZENV & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZENV
- ARMP
- Stock Information
- Founded
- ZENV 2005
- ARMP 2016
- Country
- ZENV Brazil
- ARMP United States
- Employees
- ZENV N/A
- ARMP N/A
- Industry
- ZENV Computer Software: Prepackaged Software
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ZENV Technology
- ARMP Health Care
- Exchange
- ZENV Nasdaq
- ARMP Nasdaq
- Market Cap
- ZENV 80.2M
- ARMP 73.8M
- IPO Year
- ZENV 2021
- ARMP N/A
- Fundamental
- Price
- ZENV $2.11
- ARMP $1.49
- Analyst Decision
- ZENV
- ARMP Strong Buy
- Analyst Count
- ZENV 0
- ARMP 1
- Target Price
- ZENV N/A
- ARMP $7.00
- AVG Volume (30 Days)
- ZENV 103.8K
- ARMP 15.2K
- Earning Date
- ZENV 04-29-2025
- ARMP 03-20-2025
- Dividend Yield
- ZENV N/A
- ARMP N/A
- EPS Growth
- ZENV N/A
- ARMP N/A
- EPS
- ZENV N/A
- ARMP N/A
- Revenue
- ZENV $173,594,726.00
- ARMP $5,174,000.00
- Revenue This Year
- ZENV $28.66
- ARMP $8.43
- Revenue Next Year
- ZENV $2.98
- ARMP N/A
- P/E Ratio
- ZENV N/A
- ARMP N/A
- Revenue Growth
- ZENV 23.49
- ARMP 14.24
- 52 Week Low
- ZENV $1.02
- ARMP $1.39
- 52 Week High
- ZENV $3.88
- ARMP $4.25
- Technical
- Relative Strength Index (RSI)
- ZENV 64.05
- ARMP 27.20
- Support Level
- ZENV $1.41
- ARMP $1.63
- Resistance Level
- ZENV $1.60
- ARMP $1.81
- Average True Range (ATR)
- ZENV 0.16
- ARMP 0.16
- MACD
- ZENV 0.07
- ARMP -0.05
- Stochastic Oscillator
- ZENV 94.59
- ARMP 15.62
About ZENV Zenvia Inc.
Zenvia Inc provides a platform that enables companies to create unique journeys for their end customers across a variety of channels. The company operates in two reportable segments namely CPaaS and SaaS. It has a geographic presence in Brazil, the USA, Argentina, Mexico, and Others. The company generates the majority of its revenue from Brazil.
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.